The potential for chemotherapy-free strategies in mantle cell lymphoma.
Explore this paper's citation graph
Summary
Challenges including chronic or unexpected toxicities, the rational vs practical development of combinations, and the financial acceptability of new strategies abound abound mean the nonchemotherapy era is here: how it unfolds will depend on how the authors meet these challenges.
- Type
- review
- Published
- 2017-10-26
- Cited by
- 11
- References
- 58
- Access
- Open access
- OpenAlex
- https://openalex.org/W2756217023
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:206953669
Keywords
Mantle cell lymphoma, Chemotherapy, Medicine, Oncology, Clinical trial
References
- Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
- Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
- The Imperative for a New Approach to Toxicity Analysis in Oncology Clinical Trials.
- A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma.
- Mantle cell lymphoma epidemiology: a population-based study in France
- Active idiotypic vaccination versus control immunotherapy for follicular lymphoma.
- Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.
- Durable Responses with the Metronomic Regimen RT-PEPC in Elderly Patients with Recurrent Mantle Cell Lymphoma
- Real world data on primary treatment for mantle cell lymphoma: a Nordic Lymphoma Group observational study.
- Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
- Calreticulin exposure dictates the immunogenicity of cancer cell death
- Allogeneic stem cell transplantation for mantle cell lymphoma—final report from the prospective trials of the East German Study Group Haematology/Oncology (OSHO)
- Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).
- Cell Cycle Reprogramming for PI3K Inhibition Overrides Relapse-Specific C481S BTK Mutation Revealed by Longitudinal Functional Genomics in Mantle Cell Lymphoma
- SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma – a Nordic Lymphoma Group study
- Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma.
- Complex karyotype is associated with aggressive disease and shortened progression-free survival in patients with newly diagnosed mantle cell lymphoma.
- Importance of cyclophosphamide-induced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice.
- Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
- Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial.
Cited by
- Current trials for frontline therapy of mantle cell lymphoma
- Pediatric lymphoma may develop by "one-step" cell transformation of a lymphoid cell
- Dynamic molecular monitoring reveals that SWI–SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma
- Survival Outcomes of Younger Patients With Mantle Cell Lymphoma Treated in the Rituximab Era.
- Lenalidomide for the treatment of mantle cell lymphoma
- The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax
- As the world turns, evolving lymphoma classifications - past, present and future.
- G Protein-Coupled Estrogen Receptor Agonist G-1 Inhibits Mantle Cell Lymphoma Growth in Preclinical Models
- Molecular determinants of outcomes in relapsed or refractory mantle cell lymphoma treated with ibrutinib or temsirolimus in the MCL3001 (RAY) trial
- Secondary malignancies among mantle cell lymphoma patients.
- Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma
Related papers
- Mantle cell lymphoma: established therapeutic options and future directions
- Toward new treatments for mantle-cell lymphoma?
- Multiple lymphomatous polyposis: A presentation for mantle cell lymphoma
- [Mantle Cell Lymphoma - Cutting edge Dia-gnostics and Treatment Approaches].
- Mantle cell lymphoma mimicking chronic lymphocytic leukemia/small lymphocytic lymphoma on flow cytometry
- Mantle cell lymphoma treatment: plus ça change….
- Research progress of targeted agents in the treatment of mantle cell lymphoma
- Management of mantle cell lymphoma.
- Mantle cell lymphoma as a component of composite lymphoma: clinicopathologic parameters and biologic implications.
- Mantle cell lymphoma and diffuse large B‐cell lymphoma of the testis: a unique case of composite non‐Hodgkin lymphoma